MKX-AS1 Gene Expression Associated with Variation in Drug Response to Oxaliplatin and Clinical Outcomes in Colorectal Cancer Patients.
- Resource Type
- Article
- Authors
- Gonzalez, Ricardo D.; Small, George W.; Green, Adrian J.; Akhtari, Farida S.; Motsinger-Reif, Alison A.; Quintanilha, Julia C. F.; Havener, Tammy M.; Reif, David M.; McLeod, Howard L.; Wiltshire, Tim
- Source
- Pharmaceuticals (14248247). May2023, Vol. 16 Issue 5, p757. 16p.
- Subject
- *GENE expression
*CANCER prognosis
*GENOME-wide association studies
*GENETIC variation
*TREATMENT effectiveness
*GENE expression profiling
- Language
- ISSN
- 1424-8247
Oxaliplatin (OXAL) is a commonly used chemotherapy for treating colorectal cancer (CRC). A recent genome wide association study (GWAS) showed that a genetic variant (rs11006706) in the lncRNA gene MKX-AS1 and partnered sense gene MKX could impact the response of genetically varied cell lines to OXAL treatment. This study found that the expression levels of MKX-AS1 and MKX in lymphocytes (LCLs) and CRC cell lines differed between the rs11006706 genotypes, indicating that this gene pair could play a role in OXAL response. Further analysis of patient survival data from the Cancer Genome Atlas (TCGA) and other sources showed that patients with high MKX-AS1 expression status had significantly worse overall survival (HR = 3.2; 95%CI = (1.17–9); p = 0.024) compared to cases with low MKX-AS1 expression status. Alternatively, high MKX expression status had significantly better overall survival (HR = 0.22; 95%CI = (0.07–0.7); p = 0.01) compared to cases with low MKX expression status. These results suggest an association between MKX-AS1 and MKX expression status that could be useful as a prognostic marker of response to OXAL and potential patient outcomes in CRC. [ABSTRACT FROM AUTHOR]